gel drug increased the risk of cancer and death.
FDA believes there is some evidence to show that repeated three times with Regranex than in patients treated with increased risk of cancer death.
FDA announced that, for an insurance plan database of adult patients with diabetes study found that, in January 1998 to 2003, three months, the patient's
cancer mortality has increased, but have not yet identified specific types of cancer, but also did not say how much of this study included patients, FDA
spokeswoman declined to comment on. But they added that, as early as in the 2001 study, found patients who used Regranex than in patients without the use of
such drugs a high proportion of cancer.
However, FDA also add that, in fact, diabetes itself does not cure the leg and foot ulcers there are also dangerous, so patients with diabetic foot for each
one, they should first weigh the use of
Regranex the pros and cons and then decide whether to use.
Johnson & Johnson in the Regranex spokeswoman said the manufacturing sector, in accordance with guidance in the use Regranex
Is safe, the company is working with the FDA to actively deal with the incident. However, when asked to provide more detailed information, the spokeswoman
did not immediately respond.
As a result, Johnson & Johnson in New York, the stock market fell 8 cents.
Diabetes blood sugar content exceeding, their sense of the foot due to nerve damage and diminished, it can easily lead to leg and foot wounds. The Regranex
was approved in 1997 by the United States for the treatment of diabetic foot ulcers
